• Biodesix to Announce Results of VeriStrat® Biomarker Study

    May 21, 2013 Independent Phase III Data to Be Presented at the 2013 ASCO Annual Meeting Biodesix, Inc., announced that final results of the first completed biomarker-stratified, validation study in oncology will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31st – June 4th, 2013. The Randomized Proteomic Stratified Phase III Study of Second Line ... Read more
  • Biodesix Closes Series D Financing

    April 12, 2013 Biodesix, Inc., a molecular diagnostics company advancing the development of innovative products for personalizing medicine, announced today that the company closed on $8.8 million in a follow-on sale of its Series D preferred shares.  All funds were provided by existing shareholders of the company.  The investment will be used for ongoing development of the company’s ... Read more
  • Peer-Reviewed Study Confirms VeriStrat® Test from Biodesix Provides Useful Information for Physicians in Managing Patients with Lung Cancer

    April 2, 2013 Physicians Adopting Novel Serum Test to Help Recommend Course of Treatment for Patients with Advanced Disease Biodesix, Inc., a molecular diagnostic company dedicated to personalizing medicine, today announced the online release of a peer-reviewed study demonstrating that physicians are using the company’s VeriStrat test to help guide treatment decisions for patients with advanced non-small lung cell cancer (NSCLC). ... Read more
  • Biodesix’ Heinrich Roder Presents at 2013 Biomarker Summit

    March 18, 2013 Session Examines Use of Circulating Proteins to Define Novel Disease States Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that Chief Technology Officer Heinrich Roder, DPhil will present at the 6th Oncology Biomarkers Conference as part of the 2013 Biomarker Summit taking place in San Francisco, March 20-22, 2013. Dr. Roder ... Read more
  • VeriStrat® Provides Oncologists with More Information to Personalize Therapy for Elderly Patients With Lung Cancer

    February 20, 2013 Data Published in Journal of Thoracic Oncology A new study published online ahead of print in the Journal of Thoracic Oncology concludes that Biodesix’ VeriStrat test was predictive of survival outcomes between erlotinib and gemcitabine. The study, “A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in ... Read more
  • VeriStrat® Test Predicts Differential Treatment Benefit between Chemotherapy and Targeted Therapy for Lung Cancer Patients

    September 6, 2012 Encouraging New Data Presented at Chicago Multidisciplinary Symposium in Thoracic Oncology Results from the VeriStrat analysis of serum or plasma samples taken from a Phase II study evaluating erlotinib, gemcitabine, and erlotinib plus gemcitabine in elderly advanced NSCLC patients were presented today  at the Chicago Multidisciplinary Symposium  in Thoracic Oncology. The retrospective analysis showed that the VeriStrat test was ... Read more
  • Biodesix Closes Series D Financing

    August 29, 2012 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for the Company’s first product VeriStrat®, a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer (NSCLC).  Funding will also ... Read more
  • Biodesix Announces New VeriStrat® Data to be Presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

    August 23, 2012 Biodesix today announced that VeriStrat results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. The first study will be presented by Karen Reckamp, MD (City of Hope Comprehensive Cancer Center) and reports on the analysis of pre-treatment serum samples from a Phase II study evaluating ... Read more
  • Biodesix Appoints Vice President of Clinical Development & Medical Affairs

    July 17, 2012 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced the appointment of Dominic Spinella, Ph.D., as Vice President of Clinical Development & Medical Affairs. Rounding out the management team, Dr. Spinella joins Biodesix to provide leadership for all clinical development operations. He will be based in the company’s Boulder, CO ... Read more
  • Biodesix’ Proteomic Analysis of Innovative Immunotherapy Clinical Trial in Pancreas Cancer presented at European Society of Medical Oncology’s (ESMO) World Congress on Gastrointestinal Cancer

    June 27, 2012 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced the presentation of initial results of their proteomic analysis of GlobeImmune’s Phase 2 clinical trial in pancreas cancer at the European Society of Medical Oncology’s, 14th World Congress on Gastrointestinal Cancer in Barcelona, Spain on 27 June 2012. This marks the ... Read more